Genmab Announces Progress with DuoBody(tm) Platform
Genmab A/S
20.12.2011 08:24
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- DuoBody-ADC research collaboration with undisclosed pharma company
Copenhagen, Denmark; December 20, 2011 - Genmab A/S (OMX: GEN) announced today
that the company has entered a research collaboration with an as yet
undisclosed, new large pharmaceutical partner to investigate a bispecific
antibody-drug conjugate using Genmab's DuoBody technology in combination with a
novel antibody-drug conjugate technology platform from the pharma company. If
successful, the parties may decide to enter into a license agreement to further
develop a new DuoBody-ADC product. The target in the collaboration is
clinically validated and expressed on solid tumors.
'This research collaboration with a large pharma company marks a first step in
our strategy to sign different types of partnership based on our innovative
bispecific antibody technology. This partnership will help us to investigate
the use of our DuoBody platform in creating more effective treatments for
cancer,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
This agreement will not have a material impact on Genmab's 2011 financial
guidance.
About the DuoBody platform
Genmab's proprietary DuoBody platform creates human bispecific antibodies which
bind to two different epitopes, on the same or different disease targets.
Bispecific antibodies have the potential to be more potent and efficacious than
other antibody therapeutics due to this increased specificity. The DuoBody
technology platform uses a natural process to create bispecific antibodies
which are ready for therapeutic application without recloning into a
therapeutic format. In addition, any antibody sequence can be applied and
combined for the generation of new bispecific antibodies via the DuoBody
platform. Large scale manufacturing of DuoBody molecules is based on scalable
processes. Bispecific antibodies created using the DuoBody platform have
possible application in oncology, autoimmune, central nervous system, and
infectious diseases.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 37
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=372481
News Source: NASDAQ OMX
20.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Genmab A/S
20.12.2011 08:24
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- DuoBody-ADC research collaboration with undisclosed pharma company
Copenhagen, Denmark; December 20, 2011 - Genmab A/S (OMX: GEN) announced today
that the company has entered a research collaboration with an as yet
undisclosed, new large pharmaceutical partner to investigate a bispecific
antibody-drug conjugate using Genmab's DuoBody technology in combination with a
novel antibody-drug conjugate technology platform from the pharma company. If
successful, the parties may decide to enter into a license agreement to further
develop a new DuoBody-ADC product. The target in the collaboration is
clinically validated and expressed on solid tumors.
'This research collaboration with a large pharma company marks a first step in
our strategy to sign different types of partnership based on our innovative
bispecific antibody technology. This partnership will help us to investigate
the use of our DuoBody platform in creating more effective treatments for
cancer,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
This agreement will not have a material impact on Genmab's 2011 financial
guidance.
About the DuoBody platform
Genmab's proprietary DuoBody platform creates human bispecific antibodies which
bind to two different epitopes, on the same or different disease targets.
Bispecific antibodies have the potential to be more potent and efficacious than
other antibody therapeutics due to this increased specificity. The DuoBody
technology platform uses a natural process to create bispecific antibodies
which are ready for therapeutic application without recloning into a
therapeutic format. In addition, any antibody sequence can be applied and
combined for the generation of new bispecific antibodies via the DuoBody
platform. Large scale manufacturing of DuoBody molecules is based on scalable
processes. Bispecific antibodies created using the DuoBody platform have
possible application in oncology, autoimmune, central nervous system, and
infectious diseases.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 37
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=372481
News Source: NASDAQ OMX
20.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------